The estimated Net Worth of Daniel Lang is at least 17.2 千$ dollars as of 16 September 2022. Daniel Lang owns over 12,500 units of Athenex Inc stock worth over 17,183$ and over the last 2 years he sold ATNX stock worth over 0$. In addition, he makes 0$ as Senior Director - Corporate Development、 President - Axis Therapeutics Limited at Athenex Inc.
Daniel has made over 1 trades of the Athenex Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 12,500 units of ATNX stock worth 2,500$ on 16 September 2022.
The largest trade he's ever made was exercising 12,500 units of Athenex Inc stock on 16 September 2022 worth over 2,500$. On average, Daniel trades about 6,250 units every 0 days since 2022. As of 16 September 2022 he still owns at least 85,913 units of Athenex Inc stock.
You can see the complete history of Daniel Lang stock trades at the bottom of the page.
Dr. Daniel Lang M.D. serves as Senior Director - Corporate Development, President - Axis Therapeutics Limited of the Company. Dr. Lang joins Axis and Athenex to lead the operations of the company's T-cell receptor-engineered T cells (TCR-T) immunotherapy platform for oncology and to assist with corporate development strategy for Athenex. In this new role, Dr. Lang will report to Dr. Johnson Lau, Chief Executive Officer of Athenex and Axis, and will work closely with the management teams of both companies. Dr. Lang has more than 25 years of experience as a physician, scientist and investor. Most recently, he was the Chief Investment Officer of RS Value, an investment franchise of Victory Capital, overseeing the RS Value strategies, as well as an analyst and portfolio manager for healthcare investments since 2009. Prior to RS Value, Dr. Lang was an analyst at Farallon Capital Management, a global multi-strategy hedge fund, responsible for healthcare investments. Dr. Lang started his career as a physician scientist, completing a cardiology fellowship at the University of California, San Francisco. He earned his B.A. in Chemistry from Cornell University and M.D. from Weill Cornell Medical College.
Daniel's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Over the last 7 years, insiders at Athenex Inc have traded over 33,215,399$ worth of Athenex Inc stock and bought 5,920,005 units worth 73,651,360$ . The most active insiders traders include Advisors Llcperceptive Life...、Song Yi Zhang、Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of 10,843$. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth 125$.
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Athenex Inc executives and other stock owners filed with the SEC include: